-

BrainTale Cofounders to Speak During EuroNeuro 2021 Conference

PARIS--(BUSINESS WIRE)--BrainTale, an innovative French company dedicated to neurological disorders and brain injured patient’s management with its portfolio of digital medical devices in neurology and intensive care, announces the featuring of two of its cofounders and Scientific Advisory board members, Professors Lionel Velly and Louis Puybasset during EuroNeuro 2021 held digitally on April 14th – 16th 2021.

Cofounders and members of the Scientific Advisory Board of the company will share their insights and perspectives about clinical practice in intensive care, and notably the improved management of comatose patients. EuroNeuro 2021 conference is the outstanding event for Key Opinion leaders to share latest information and practices in clinical neurosciences.

Co-President of the conference and cofounder, Professor Lionel Velly, member of the Scientific Advisory board of the company has joined the “Long term post traumatic neuroinflammation” roundtable, chaired by Professor Tarek Sharshar on Wednesday April 14th.

Professor Louis Puybasset, cofounder and President of Braintale’ Scientific Advisory board

- Together with Pr Nicolas Bruder, has chaired the Roche Symposium entitled “Biomarker of Brain damage: review of clinical utility” and shared his vision about “S100B and subarachnoid hemorrhage monitoring” on Wednesday April 14th at 12:30 pm;
- Will chair Session three, dedicated to “Prognostication after Brain Injury” on Friday April 16th at 2 pm;
- Will lecture on “Quantitative imaging to adapt prognostication” on Friday April 16th at 3:30 pm;
- and will chair Session four, dedicated to “Enhancing recovery” on Friday April 16th at 4 pm.

About BrainTale
BrainTale is an innovative company opening a new era in medicine by providing physicians with clinically validated prognostic solutions for the management of brain injured patients through sensitive and reliable measurements of brain white-matter microstructure alterations. Building on more than 15 years in clinical development, BrainTale’s products are developed collaboratively to address medical need and fulfill expectations of healthcare professionals and patients alike.
Since its inception in 2018, the company has set up a complete quality management system and is now ISO :13485 :2016 certified, with a suite of products available on the European market.
For more information, please visit www.braintale.fr

Contacts

Julie Rachline, CEO julie.rachline@braintale.eu +33662420358

BrainTale

Details
Headquarters: strasbourg, France
CEO: julie Rachline
Employees: 19
Organization: PRI

Release Versions
Hashtags

Contacts

Julie Rachline, CEO julie.rachline@braintale.eu +33662420358

Social Media Profiles
More News From BrainTale

BrainTale Announces First Patient Enrolled in Investigator-Sponsored Prospective Multi-Centric Study CALDIFF to Clinically Validate One of Its Predictive Biomarkers

STRASBOURG, France--(BUSINESS WIRE)--BrainTale, a medtech deciphering white matter to enable better brain care, spin-off of the Paris Region Greater Hospitals, announced today the enrollment of the first patient in the CALDIFF, investigator-sponsored clinical trial, sponsored by the Paris Region Greater Hospitals (Assistance Publique - Hôpitaux de Paris) and led by Professor Fanny Mochel (APHP220801, NCT05911919). The study has been designed to clinically demonstrate the potential of a BrainTal...

BrainTale Biomarker Platform Supports Drug Development in Demyelinating Disease

STRASBOURG, France--(BUSINESS WIRE)--BrainTale, a medtech deciphering white matter to enable better brain care, spin-off of the Paris Region Greater Hospitals announces the publication of the article by Marianne Golse in the peer-reviewed journal Brain entitled “Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy“ supporting the benefits of its biomarker platform as non-invasive reliable and objective lesion-assessment tool in the drug development...

Parkinson’s Disease: A Digital Biomarker Platform for Differentiated Diagnosis

STRASBOURG, France--(BUSINESS WIRE)--BrainTale, a medtech deciphering white matter to enable better brain care, spin-off of the Paris Region Greater Hospitals, attended the European Academy of Neurology (EAN) congress held in Helsinki, Finland, from June 29 to July 02, 2024. Data presented during the oral presentation by Vincent Perlbarg, co-founder and scientific director, and Martin Grange, data scientist, demonstrated the potential of BrainTale's solution to specifically differentiate Parkin...
Back to Newsroom